Unknown PHASE2 INTERVENTIONAL 2-arm NCT04181372

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

A Phase II Study of Neoadjuvant Double-drug Chemotherapy With Platinum Plus Anlotinib Hydrochloride in Stage III(N2) Non-small-cell Lung Cancer

Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Conditions Stage III Non-small-cell Lung Cancer

Interventions Anlotinib hydrochloride platinum-based chemotherapy medicine

Updated 5 times since 2019 Last updated: Nov 26, 2019 Started: Dec 31, 2019 Primary completion: Aug 1, 2021 Completion: Aug 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04181372, this PHASE2 trial focuses on Stage III Non-small-cell Lung Cancer and remains ongoing. Sponsored by The First Affiliated Hospital of Guangzhou Medical University, it has been updated 5 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Not Yet Recruiting PHASE2
Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Guangzhou Medical University

Data source: The First Affiliated Hospital of Guangzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China